Articaine Hydrochloride

證據等級: L5

預測適應症: 0 個

Articaine Hydrochloride: Dental Local Anesthetic — Drug Repurposing Evaluation

One-Sentence Summary

Articaine Hydrochloride is an amide-type local anesthetic primarily used in dentistry for infiltration and nerve block anesthesia during dental procedures. The TxGNN model did not generate any repurposing predictions for this compound in the current evidence pack, likely due to insufficient DrugBank linkage or absence of this drug in the active knowledge graph nodes. With no clinical trial evidence and no literature evidence retrieved for a new indication, this evaluation serves as a data-gap documentation rather than a repurposing recommendation.

Quick Overview

Item	Content
Original Indication	Dental local anesthesia (infiltration & nerve block)
Predicted New Indication	— (No prediction generated)
TxGNN Prediction Score	— (No prediction generated)
Evidence Level	L5 — Model prediction not available; no supporting studies
Malaysia Market Status	✓ Marketed
Number of Registrations	3
Recommended Decision	Hold

Why is This Prediction Reasonable?

No repurposing prediction was generated by TxGNN for Articaine Hydrochloride in this evidence pack. The most likely reasons are:

DrugBank ID not resolved: The drugbank_id field is null in the Evidence Pack, meaning the drug could not be anchored to a node in the TxGNN knowledge graph (KG). Without a valid KG node, no link prediction can be performed.
Narrow pharmacological profile: Articaine is a dental-specific local anesthetic. Unlike systemic drugs with broad receptor interactions, its primary mechanism — voltage-gated sodium channel (Nav) blockade at peripheral nerve terminals — has a highly localised site of action, limiting the biological plausibility space for systemic disease repurposing.
Data gaps present: Both mechanism of action (MOA) and NPRA licence details were not successfully extracted from the source data, further limiting the model’s ability to generate contextually grounded predictions.

Until the DrugBank ID is confirmed and the drug is mapped into the KG, no evidence-based repurposing assessment can be completed.

Clinical Trial Evidence

Currently no related clinical trials registered for a new (non-dental) indication of Articaine Hydrochloride.

Literature Evidence

Currently no related literature available for repurposing of Articaine Hydrochloride beyond its approved dental indication.

Malaysia Market Information

The Evidence Pack confirms 3 active registrations under NPRA, but detailed licence fields (registration numbers, product names, dosage forms, and approved indication text) were not extracted in the current data pull. The table below reflects the available data:

Authorization Number	Product Name	Dosage Form	Approved Indication
—	—	—	Details not extracted (NPRA query returned 3 records; raw data needs re-parsing)

Action required: Re-run the NPRA data extraction pipeline to populate licence-level fields for this drug.

Safety Considerations

Please refer to the package insert for safety information. No warnings, contraindications, or drug interaction data were available in the current Evidence Pack.

Note for clinical pharmacists: Articaine is generally known to carry risks of methemoglobinaemia and CNS/cardiovascular toxicity at high doses, common to all amide local anesthetics. These should be confirmed against the registered Malaysian package insert before any clinical use.

Conclusion and Next Steps

Decision: Hold

Rationale: No TxGNN repurposing prediction was generated due to an unresolved DrugBank ID and missing KG linkage; without a valid graph node, no meaningful repurposing inference can be made for Articaine Hydrochloride at this time.

To proceed, the following is needed:

Resolve DrugBank ID: Search DrugBank for “Articaine” (likely DB00348) and confirm the mapping; re-run KG prediction with the verified ID.
Extract NPRA licence details: Re-parse the raw NPRA response to populate product name, dosage form, and approved indication text for the 3 registered products.
Obtain MOA data: Query DrugBank API with the confirmed ID to retrieve mechanism of action and pharmacological targets.
Download Malaysian package insert: Retrieve from the NPRA e-register to fill safety warnings and contraindications fields.
Re-run Evidence Pack generation: After resolving the above gaps (DG001, DG002), regenerate the Evidence Pack at v5 and re-evaluate for repurposing candidates.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.